ArticleDermatology and therapy2026
Efficacy of Upadacitinib in Patients with Atopic Dermatitis of the Head and Neck Region.
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHead and neck atopic dermatitis (AD) is difficult to treat. We evaluated the efficacy of upadacitinib versus placebo in patients with head and neck AD in a post hoc analysis of Measure Up 1 (NCT03569293) and Measure Up 2 (NCT03607422).
methodsPatients with head and neck AD (overall and stratified by baseline head and neck Eczema Area and Severity Index [EASI]) received upadacitinib 15 mg, upadacitinib 30 mg, or placebo. Efficacy assessments included achievement of stringent targets (head and neck EASI ≤ 0.3 [almost clear], EASI 90 [near-complete clearance], EASI 100 [complete clearance], and patient-reported outcomes [PROs]) through week 16.
resultsAt week 16, more patients achieved head and neck EASI ≤ 0.3, EASI 90, and EASI 100 with upadacitinib 15 mg (46.8%, 41.9%, 29.1%) and upadacitinib 30 mg (58.0%, 56.5%, 42.4%) versus placebo (13.5%, 11.5%, 9.0%), respectively. Similar patterns, including PRO outcomes, were observed across head and neck AD severity subgroups. Total EASI head and neck median percentage reduction from baseline at week 16 was 87.8% for upadacitinib 15 mg and 96.3% for upadacitinib 30 mg.
conclusionsUpadacitinib substantially improved skin and PRO outcomes in patients with head and neck AD, including those with moderate or severe baseline involvement.
trial registrationClinicalTrials.gov Measure Up 1 (NCT03569293) and Measure Up 2 (NCT03607422).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.